GFS Advisors LLC Purchases New Shares in Danaher Corporation $DHR

GFS Advisors LLC purchased a new stake in Danaher Corporation (NYSE:DHR) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 3,245 shares of the conglomerate’s stock, valued at approximately $641,000.

A number of other institutional investors have also made changes to their positions in DHR. GHP Investment Advisors Inc. raised its holdings in shares of Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after buying an additional 99 shares during the last quarter. Sierra Ocean LLC raised its holdings in shares of Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after buying an additional 76 shares during the last quarter. Red Tortoise LLC raised its holdings in shares of Danaher by 175.0% in the second quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after buying an additional 98 shares during the last quarter. Smallwood Wealth Investment Management LLC bought a new stake in Danaher during the 1st quarter worth about $31,000. Finally, Dunhill Financial LLC raised its holdings in Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock worth $34,000 after purchasing an additional 67 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

Shares of DHR stock opened at $202.53 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The stock has a market cap of $145.02 billion, a PE ratio of 43.09, a price-to-earnings-growth ratio of 2.88 and a beta of 0.77. The stock has a 50-day moving average of $200.66 and a 200-day moving average of $197.16. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. During the same period in the previous year, the firm earned $1.72 EPS. Danaher’s quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a $0.32 dividend. The ex-dividend date is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s payout ratio is currently 27.23%.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the subject of several recent research reports. Rothschild & Co Redburn reissued a “neutral” rating and set a $220.00 price objective (down from $245.00) on shares of Danaher in a report on Wednesday. Guggenheim reissued a “buy” rating and set a $250.00 price objective on shares of Danaher in a report on Wednesday, July 23rd. Robert W. Baird boosted their price objective on Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a report on Friday, July 18th. UBS Group dropped their price objective on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Finally, Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Friday, June 27th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $244.60.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.